CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
0.630
+0.024 (3.96%)
At close: Mar 9, 2026, 4:00 PM EDT
0.630
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
CollPlant Biotechnologies Revenue
CollPlant Biotechnologies had revenue of $77.00K in the quarter ending September 30, 2025, with 1,825.00% growth. This brings the company's revenue in the last twelve months to $2.48M, up 280.77% year-over-year. In the year 2024, CollPlant Biotechnologies had annual revenue of $515.00K, down -95.30%.
Revenue (ttm)
$2.48M
Revenue Growth
+280.77%
P/S Ratio
3.66
Revenue / Employee
$43,421
Employees
57
Market Cap
8.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 515.00K | -10.44M | -95.30% |
| Dec 31, 2023 | 10.96M | 10.66M | 3,565.22% |
| Dec 31, 2022 | 299.00K | -15.34M | -98.09% |
| Dec 31, 2021 | 15.64M | 9.50M | 154.86% |
| Dec 31, 2020 | 6.14M | 3.82M | 164.75% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 5.20M |
| SeaStar Medical Holding | 881.00K |
| Iterum Therapeutics | 390.00K |
| Cardio Diagnostics Holdings | 15.78K |
| Alaunos Therapeutics | 6.00K |
| Ernexa Therapeutics | 1,000.00 |
CLGN News
- 11 days ago - CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler - PRNewsWire
- 14 days ago - CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex - PRNewsWire
- 20 days ago - CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments - PRNewsWire
- 4 weeks ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING - PRNewsWire
- 3 months ago - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire
- 3 months ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada - PRNewsWire
- 5 months ago - CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology - PRNewsWire